{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:08:16Z","timestamp":1791385696243,"version":"4.3.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>For patients with interstitial lung diseases (ILDs) presenting with a progressive pulmonary fibrosis (PPF) phenotype, current knowledge of disease characteristics at diagnosis, patient journey, and treatment is limited. This study aimed to describe demographics and clinical experiences of patients presenting with PPF in a European real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were analysed from the Adelphi Real World PPF-ILD Disease Specific Programme\u2122, a cross-sectional survey of pulmonologists and rheumatologists in five European countries (France, Germany, Italy, Spain, United Kingdom) and internal medicine specialists (France) from April to October 2022. Physicians provided data for up to 12 consecutive patients with physician-confirmed ILD with a progressive phenotype other than idiopathic pulmonary fibrosis. Analyses were descriptive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 265 physicians reported on 1,335 patients. Mean (standard deviation) age at survey date was 60.4 (11.6) years, 91.2% were white, 58.1% female, 44.0% non-smokers. Most patients (63.3%) first consulted a primary care physician. There was a mean delay of 7.8 (22.7) months between first ILD symptom and healthcare professional visit, and another 7.7 (12.8) months to ILD diagnosis. At survey date, 47.7% of patients had physician-reported moderate ILD, 42.3% had mild ILD and 10.0% had severe ILD. Disease progression was reported in the 12 months prior to the survey for 19.5% of patients; of these, progression was based on worsening symptom in 27.3% and lung function decline in 25.8%. For patients experiencing symptoms prior to ILD diagnosis (72.8%), the most common symptoms were dyspnoea on exertion (80.5%) and cough (57.8%). Overall, 17.4% of patients were misdiagnosed prior to ILD diagnosis, with chronic obstructive pulmonary disease suspected in 39.2% of them. The most frequent comorbidities were anxiety (16.9%) and gastroesophageal reflux (15.5%). Although 77.8% of patients were receiving treatment for ILD at survey date, 15.6% of patients had never been prescribed treatment for ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This real-world study expands our understanding of patients, diagnostic delays and treatment gaps experienced by patients diagnosed with PPF in Europe. There was a mean delay of 15.5 months between first ILD symptoms and ILD diagnosis. Given the progressive nature of PPF, diagnostic delay may lead to poor outcomes, including shorter survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>N\/a.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-024-02995-9","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T14:02:02Z","timestamp":1728482522000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment patterns and patient journey in progressive pulmonary fibrosis: a cross-sectional survey"],"prefix":"10.1186","volume":"25","author":[{"given":"Nazia","family":"Chaudhuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria C.","family":"Amatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver-Thomas","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"issue":"9","key":"2995_CR1","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"issue":"151","key":"2995_CR2","doi-asserted-by":"publisher","first-page":"180100","DOI":"10.1183\/16000617.0100-2018","volume":"28","author":"V Cottin","year":"2019","unstructured":"Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. 2019;28(151):180100.","journal-title":"Eur Respir Rev"},{"issue":"150","key":"2995_CR3","doi-asserted-by":"publisher","first-page":"180076","DOI":"10.1183\/16000617.0076-2018","volume":"27","author":"V Cottin","year":"2018","unstructured":"Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180076.","journal-title":"Eur Respir Rev"},{"issue":"3","key":"2995_CR4","doi-asserted-by":"publisher","first-page":"00170","DOI":"10.1183\/23120541.00170-2018","volume":"5","author":"J Kaunisto","year":"2019","unstructured":"Kaunisto J, Salomaa ER, Hodgson U, Kaarteenaho R, Kankaanranta H, Koli K, et al. Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry. ERJ Open Res. 2019;5(3):00170\u20132018.","journal-title":"ERJ Open Res"},{"issue":"5","key":"2995_CR5","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1007\/s12325-018-0693-1","volume":"35","author":"H Strongman","year":"2018","unstructured":"Strongman H, Kausar I, Maher TM. Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK. Adv Ther. 2018;35(5):724\u201336.","journal-title":"Adv Ther"},{"issue":"1","key":"2995_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12931-019-1043-9","volume":"20","author":"L Snyder","year":"2019","unstructured":"Snyder L, Neely ML, Hellkamp AS, O\u2019Brien E, de Andrade J, Conoscenti CS, et al. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res. 2019;20(1):105.","journal-title":"Respir Res"},{"issue":"10","key":"2995_CR7","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMra2005230","volume":"383","author":"M Wijsenbeek","year":"2020","unstructured":"Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020;383(10):958\u201368.","journal-title":"N Engl J Med"},{"issue":"5","key":"2995_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/MCP.0000000000000908","volume":"28","author":"C Valenzuela","year":"2022","unstructured":"Valenzuela C, Cottin V. Epidemiology and real-life experience in progressive pulmonary fibrosis. Curr Opin Pulm Med. 2022;28(5):407\u201313.","journal-title":"Curr Opin Pulm Med"},{"issue":"2","key":"2995_CR9","first-page":"e54268","volume":"16","author":"RK Man","year":"2024","unstructured":"Man RK, Gogikar A, Nanda A, Janga LSN, Sambe HG, Yasir M, Ramphall S. A comparison of the effectiveness of nintedanib and pirfenidone in treating idiopathic pulmonary fibrosis: a systematic review. Cureus. 2024;16(2):e54268.","journal-title":"Cureus"},{"key":"2995_CR10","unstructured":"European Medicines Agency. Ofev\u00ae (nintedanib): Summary of product characteristics 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ofev-epar-product-information_en.pdf"},{"key":"2995_CR11","unstructured":"U.S. Food & Drug Administration. OFEV\u00ae (nintedanib): Prescribing information 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/205832Orig1s016lbl.pdf"},{"key":"2995_CR12","unstructured":"European Medicines Agency. Esbriet\u00ae (pirfenidone): Summary of product characteristics 2022. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002154\/WC500103049.pdf"},{"key":"2995_CR13","unstructured":"U.S. Food & Drug Administration. ESBRIET\u00ae (pirfenidone): Prescribing information 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022535s012,208780s002lbl.pdf"},{"key":"2995_CR14","unstructured":"Behr J, Kreuter M, Prasse A, Guenther A, Bonella F, Pittrow D et al. Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry. Poster presented at ERS Congress. 2024; 7\u201311 September; Vienna, Austria 2024."},{"issue":"suppl 67","key":"2995_CR15","first-page":"PA2882","volume":"62","author":"L Lobo","year":"2023","unstructured":"Lobo L, Liu Y, Li P, Ramaswamy M, Swaminathan AC, Veeraraghavan S, et al. Characteristics of patients with progressive fibrosing ILDs in the ILD-PRO Registry. Eur Respir J. 2023;62(suppl 67):PA2882.","journal-title":"Eur Respir J"},{"key":"2995_CR16","doi-asserted-by":"publisher","first-page":"743977","DOI":"10.3389\/fmed.2021.743977","volume":"8","author":"CR Copeland","year":"2021","unstructured":"Copeland CR, Lancaster LH. Management of progressive fibrosing interstitial lung diseases (PF-ILD). Front Med (Lausanne). 2021;8:743977.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"2995_CR17","doi-asserted-by":"publisher","first-page":"2000085","DOI":"10.1183\/13993003.00085-2020","volume":"55","author":"KK Brown","year":"2020","unstructured":"Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020;55(6):2000085.","journal-title":"Eur Respir J"},{"issue":"4","key":"2995_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431\u201340.","journal-title":"Am J Respir Crit Care Med"},{"key":"2995_CR19","doi-asserted-by":"publisher","first-page":"799912","DOI":"10.3389\/fmed.2022.799912","volume":"9","author":"V Cottin","year":"2022","unstructured":"Cottin V, Teague R, Nicholson L, Langham S, Baldwin M. The burden of progressive-fibrosing interstitial lung diseases. Front Med (Lausanne). 2022;9:799912.","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"2995_CR20","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1007\/s12325-020-01384-0","volume":"37","author":"WA Wuyts","year":"2020","unstructured":"Wuyts WA, Papiris S, Manali E, Kilpelainen M, Davidsen JR, Miedema J, et al. The burden of progressive fibrosing interstitial lung disease: a DELPHI approach. Adv Ther. 2020;37(7):3246\u201364.","journal-title":"Adv Ther"},{"key":"2995_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.pupt.2018.09.003","volume":"53","author":"SE Torrisi","year":"2018","unstructured":"Torrisi SE, Vancheri A, Pavone M, Sambataro G, Palmucci S, Vancheri C. Comorbidities of IPF: how do they impact on prognosis. Pulm Pharmacol Ther. 2018;53:6\u201311.","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"2995_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12931-022-02033-6","volume":"23","author":"DM Jovanovic","year":"2022","unstructured":"Jovanovic DM, Sterclova M, Mogulkoc N, Lewandowska K, Muller V, Hajkova M, et al. Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study. Respir Res. 2022;23(1):135.","journal-title":"Respir Res"},{"issue":"143","key":"2995_CR23","doi-asserted-by":"publisher","first-page":"160027","DOI":"10.1183\/16000617.0027-2016","volume":"26","author":"GA Margaritopoulos","year":"2017","unstructured":"Margaritopoulos GA, Antoniou KM, Wells AU. Comorbidities in interstitial lung diseases. Eur Respir Rev. 2017;26(143):160027.","journal-title":"Eur Respir Rev"},{"issue":"11","key":"2995_CR24","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"2995_CR25","doi-asserted-by":"publisher","first-page":"e010352","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6(8):e010352.","journal-title":"BMJ Open"},{"issue":"12","key":"2995_CR26","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy J, Doslikova K, Davis VA, Karavali M, Piercy J. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes. Curr Med Res Opin. 2023;39(12):1707\u201315.","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"2995_CR27","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","volume":"177","author":"NS Goh","year":"2008","unstructured":"Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177(11):1248\u201354.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 4","key":"2995_CR28","doi-asserted-by":"publisher","first-page":"468A","DOI":"10.1016\/j.chest.2016.08.482","volume":"150","author":"G Cosgrove","year":"2016","unstructured":"Cosgrove G, Bianchi P, Lobodo J, Danese S, Lederer D. Understanding the patient journey of interstitial lung disease diagnosis: the intensity survey. Chest. 2016;150(Suppl 4):468A.","journal-title":"Chest"},{"key":"2995_CR29","doi-asserted-by":"publisher","first-page":"711194","DOI":"10.3389\/fmed.2021.711194","volume":"8","author":"IG van Der Sar","year":"2021","unstructured":"van Der Sar IG, Jones S, Clarke DL, Bonella F, Fourrier JM, Lewandowska K, et al. Patient reported experiences and delays during the diagnostic pathway for pulmonary fibrosis: a multinational European survey. Front Med. 2021;8:711194.","journal-title":"Front Med"},{"issue":"3","key":"2995_CR30","doi-asserted-by":"publisher","first-page":"e0151425","DOI":"10.1371\/journal.pone.0151425","volume":"11","author":"M Kreuter","year":"2016","unstructured":"Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, et al. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS ONE. 2016;11(3):e0151425.","journal-title":"PLoS ONE"},{"key":"2995_CR31","doi-asserted-by":"crossref","unstructured":"Hoyer N, Prior TS, Bendstrup E, Shaker SB. Diagnostic delay in IPF impacts progression-free survival, quality of life and hospitalisation rates. BMJ Open Respir Res. 2022;9(1).","DOI":"10.1136\/bmjresp-2022-001276"},{"key":"2995_CR32","doi-asserted-by":"publisher","first-page":"9026171","DOI":"10.1155\/2020\/9026171","volume":"2020","author":"G Ageely","year":"2020","unstructured":"Ageely G, Souza C, De Boer K, Zahra S, Gomes M, Voduc N. The impact of multidisciplinary discussion (MDD) in the diagnosis and management of fibrotic interstitial lung diseases. Can Respir J. 2020;9026171.","journal-title":"Can Respir J"},{"issue":"8","key":"2995_CR33","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1111\/resp.12850","volume":"21","author":"HE Jo","year":"2016","unstructured":"Jo HE, Glaspole IN, Levin KC, McCormack SR, Mahar AM, Cooper WA, et al. Clinical impact of the interstitial lung disease multidisciplinary service. Respirology. 2016;21(8):1438\u201344.","journal-title":"Respirology"},{"issue":"4","key":"2995_CR34","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/resp.14231","volume":"27","author":"KK Brown","year":"2022","unstructured":"Brown KK, Inoue Y, Flaherty KR, Martinez FJ, Cottin V, Bonella F, et al. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. Respirology. 2022;27(4):294\u2013300.","journal-title":"Respirology"},{"issue":"1","key":"2995_CR35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/resp.14154","volume":"27","author":"L Lancaster","year":"2022","unstructured":"Lancaster L, Bonella F, Inoue Y, Cottin V, Siddall J, Small M, Langley J. Idiopathic pulmonary fibrosis: physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. Respirology. 2022;27(1):66\u201375.","journal-title":"Respirology"},{"issue":"145","key":"2995_CR36","doi-asserted-by":"publisher","first-page":"170051","DOI":"10.1183\/16000617.0051-2017","volume":"26","author":"H Robbie","year":"2017","unstructured":"Robbie H, Daccord C, Chua F, Devaraj A. Evaluating disease severity in idiopathic pulmonary fibrosis. Eur Respir Rev. 2017;26(145):170051.","journal-title":"Eur Respir Rev"},{"issue":"1","key":"2995_CR37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12890-017-0468-5","volume":"17","author":"TM Maher","year":"2017","unstructured":"Maher TM, Molina-Molina M, Russell AM, Bonella F, Jouneau S, Ripamonti E, et al. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries. BMC Pulm Med. 2017;17(1):124.","journal-title":"BMC Pulm Med"},{"issue":"11","key":"2995_CR38","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","volume":"35","author":"M Wijsenbeek","year":"2019","unstructured":"Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells CD, et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019;35(11):2015\u201324.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"2995_CR39","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.1007\/s12325-023-02701-z","volume":"40","author":"A Lokke","year":"2023","unstructured":"Lokke A, Castello L, Pinheiro Martins P, Soulard S, Hilberg O. Burden of disease and productivity loss in the European Economic Area in patients affected by fibrosing interstitial lung disease. Adv Ther. 2023;40(12):5502\u201318.","journal-title":"Adv Ther"},{"key":"2995_CR40","doi-asserted-by":"publisher","first-page":"106333","DOI":"10.1016\/j.rmed.2021.106333","volume":"179","author":"N Dodia","year":"2021","unstructured":"Dodia N, Amariei D, Kenaa B, Corwin D, Chelala L, Britt EJ, et al. A comprehensive assessment of environmental exposures and the medical history guides multidisciplinary discussion in interstitial lung disease. Respir Med. 2021;179:106333.","journal-title":"Respir Med"},{"issue":"7","key":"2995_CR41","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1111\/resp.13163","volume":"22","author":"JD Prasad","year":"2017","unstructured":"Prasad JD, Mahar A, Bleasel J, Ellis SJ, Chambers DC, Lake F, et al. The interstitial lung disease multidisciplinary meeting: a position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology. 2017;22(7):1459\u201372.","journal-title":"Respirology"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02995-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-024-02995-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02995-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T14:04:34Z","timestamp":1728482674000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-024-02995-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2995"],"URL":"https:\/\/doi.org\/10.1186\/s12931-024-02995-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4000353\/v1","asserted-by":"object"}]},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"assertion":[{"value":"29 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received Pearl Institutional Review Board ethical exemption (22-ADRW-135) and was conducted adhering to European Pharmaceutical Market Research Association guidelines and Adelphi Real World standard operating procedures. The physicians provided written consent to participate in the DSP.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NC declares being a consultant for Boehringer Ingelheim during the development of this study, payment for consultancy activities from Boehringer Ingelheim and Roche, speaker fees from Boehringer Ingelheim, Roche and AstraZeneca, and participation in advisory boards from Boehringer Ingelheim and Roche. PS declares being a consultant for Boehringer Ingelheim during the development of this study, payment for consultancy activities and an institutional grant from PPM Services, speaker fees, participation on an advisory board and an institutional grant from Boehringer Ingelheim, institutional grants from Roche, consultancy activities for Jucabio, GlycoCore Pharma, Veracyte and Pieris, consulting and speaker fees from Chiesi, and participation on advisory boards for AstraZeneca and Structure Therapeutics. CV declares being a consultant for Boehringer Ingelheim during the development of this study. VCA is an employee of Boehringer Ingelheim International GmbH. O-TC, LL and MS are employees of Adelphi Real World. MK declares being a consultant for Boehringer Ingelheim during the development of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"364"}}